Terns Pharmaceuticals (NASDAQ:TERN) CEO Sells $571,507.77 in Stock

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) CEO Amy Burroughs sold 14,583 shares of the firm’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $39.19, for a total transaction of $571,507.77. Following the completion of the sale, the chief executive officer owned 288,976 shares in the company, valued at approximately $11,324,969.44. The trade was a 4.80% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Terns Pharmaceuticals Trading Down 0.6%

NASDAQ:TERN traded down $0.23 during trading hours on Wednesday, hitting $39.35. 1,324,631 shares of the company traded hands, compared to its average volume of 2,148,204. Terns Pharmaceuticals, Inc. has a twelve month low of $1.87 and a twelve month high of $48.26. The firm has a 50-day moving average of $38.62 and a 200 day moving average of $21.83. The stock has a market capitalization of $4.08 billion, a price-to-earnings ratio of -38.20 and a beta of -0.28.

Institutional Investors Weigh In On Terns Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in Terns Pharmaceuticals during the fourth quarter worth about $25,000. GAMMA Investing LLC boosted its holdings in shares of Terns Pharmaceuticals by 762.4% in the 4th quarter. GAMMA Investing LLC now owns 871 shares of the company’s stock worth $35,000 after acquiring an additional 770 shares in the last quarter. EverSource Wealth Advisors LLC boosted its holdings in shares of Terns Pharmaceuticals by 61.6% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,207 shares of the company’s stock worth $89,000 after acquiring an additional 841 shares in the last quarter. Vanguard Personalized Indexing Management LLC grew its position in Terns Pharmaceuticals by 5.1% during the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 18,555 shares of the company’s stock worth $750,000 after acquiring an additional 906 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Terns Pharmaceuticals by 29.4% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,377 shares of the company’s stock valued at $177,000 after purchasing an additional 994 shares in the last quarter. Institutional investors and hedge funds own 98.26% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on TERN shares. Mizuho raised their price objective on Terns Pharmaceuticals from $33.00 to $54.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 9th. Citigroup restated an “outperform” rating on shares of Terns Pharmaceuticals in a research note on Wednesday, November 26th. Truist Financial raised their target price on Terns Pharmaceuticals from $35.00 to $56.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. UBS Group raised shares of Terns Pharmaceuticals to a “strong-buy” rating in a report on Thursday, December 4th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $70.00 price objective on shares of Terns Pharmaceuticals in a research note on Wednesday, December 10th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $58.11.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.